Pharma channel feed

Pfiz­er shares the ADC da­ta that con­vinced it to start a Phase 3 lung can­cer tri­al

Last year
R&D

AS­CO ab­stracts are out, with da­ta for AD­Cs, Nim­bus' next-gen I/O drug and more

Last year
R&D

Talc claimants file class ac­tion suit ac­cus­ing J&J of fraud over bank­rupt­cy moves

Last year
Law

Eu­ro­pean Com­mis­sion fi­nal­izes joint clin­i­cal as­sess­ment rules for mem­ber coun­tries

Last year
Law

At­ro­pos Health rais­es $33M to arm doc­tors and phar­ma com­pa­nies with ev­i­dence

Last year
Health Tech

Take­da en­ters hot mol­e­c­u­lar glue space in up to $1.2B pact with De­gron

Last year
Startups
China

Fed­er­al ap­peals court sides with drug­mak­ers on 340B lim­i­ta­tions

Last year
Law

FDA ques­tions hy­po­glycemia risk for No­vo Nordisk's once-week­ly in­sulin ahead of ad­comm

Last year
FDA+

Pfiz­er an­nounces an­oth­er $1.5B in cost cuts — and plans for more to come

Last year
People

House com­mit­tee press­es FDA cen­ter di­rec­tors on do­mes­tic man­u­fac­tur­ing, LDTs

Last year
FDA+

Evotec ends gene ther­a­py busi­ness, shuts down fa­cil­i­ty in Aus­tria

Last year
Cell/Gene Tx
Manufacturing

Ver­sant has a new obe­si­ty biotech. As­traZeneca has the op­tion to buy it

Last year
Financing
Startups

No­vo Nordisk looks be­yond weight loss and di­a­betes to ex­pand in new ill­ness­es

Last year

Sen­a­tors strike bi­par­ti­san tone on more phar­ma patent re­forms

Last year
FDA+
Law

Sen. Wyden ques­tions Pfiz­er over tax rate as part of on­go­ing in­ves­ti­ga­tion

Last year
FDA+

With $5B in Chi­na sales, As­traZeneca dou­bles down on Chi­nese bio­phar­ma in­no­va­tion

Last year
China

Bris­tol My­er­s' sub­cu­ta­neous ver­sion of Op­di­vo gets ear­li­er PDU­FA date

Last year
FDA+

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

Last year
R&D

‘A new era of growth’: As­traZeneca aims for $80B rev­enue, 20 new drugs by 2030

Last year

FDA with­draws Helsinn’s ac­cel­er­at­ed ap­proval for can­cer drug af­ter com­pa­ny’s re­quest

Last year
FDA+

Ju­ry says As­traZeneca should pay Pfiz­er $107M+ over Tagris­so in­fringe­ment

Last year
Law

PTC's mus­cu­lar dy­s­tro­phy drug Translar­na to get an­oth­er re­view in the EU

Last year
FDA+

FDA ap­proves first two in­ter­change­able biosim­i­lars to Re­gen­eron's block­buster Eylea

Last year
FDA+

Study iden­ti­fies groups of peo­ple who mis­trust the FDA

Last year
FDA+
First page Previous page 54555657585960 Next page Last page
A service from the Financial Times